ENTERA BIO LTD. (ENTX) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $1.00K; Additional Paid in Capital, Common StockUSD $143.41M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $41.00K; Retained Earnings (Accumulated Deficit)USD $-136.18M.
- 2026-03-31: Common Stock, Value, IssuedUSD $1.00K; Additional Paid in Capital, Common StockUSD $139.52M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $41.00K; Retained Earnings (Accumulated Deficit)USD $-128.87M.
- 2025-12-31: Common Stock, Value, IssuedUSD $1.00K; Additional Paid in Capital, Common StockUSD $138.43M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $41.00K; Retained Earnings (Accumulated Deficit)USD $-125.37M.
- 2025-09-30: Common Stock, Value, IssuedUSD $1.00K; Additional Paid in Capital, Common StockUSD $137.54M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $41.00K; Retained Earnings (Accumulated Deficit)USD $-122.35M.
ENTERA BIO LTD. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Accumulated Other Comprehensive Income USD | Retained Earnings USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.00K | $143.41M | $41.00K | $-136.18M | $7.27M | (m) | 3 month · $624.00K 6 month · $1.30M | (m) | (m) |
| 2026-03-31 | $1.00K | $139.52M | $41.00K | $-128.87M | $10.69M | 3 month · $0.00 | 3 month · $672.00K | (m) | (m) |
| 2025-12-31 | $1.00K | $138.43M | $41.00K | $-125.37M | $13.10M | 12 month · $0.00 | 12 month · $2.75M | (m) | (m) |
| 2025-09-30 | $1.00K | $137.54M | $41.00K | $-122.35M | $15.23M | 9 month · $0.00 | 3 month · $927.00K 9 month · $2.04M | (m) | (m) |
| 2025-06-30 | $1.00K | $136.36M | $41.00K | $-119.15M | $17.26M | 3 month · $0.00 6 month · $0.00 | 3 month · $509.00K 6 month · $1.11M | (m) | (m) |
| 2025-03-31 | $1.00K | $135.83M | $41.00K | $-116.49M | $19.38M | 3 month · $0.00 | 3 month · $604.00K | (m) | (m) |
| 2024-12-31 | $1.00K | $121.97M | $41.00K | $-113.93M | $8.08M | 12 month · $0.00 | 12 month · $2.56M | (m) | (m) |
| 2024-09-30 | $1.00K | $117.98M | $41.00K | $-111.57M | $6.45M | 3 month · $0.00 9 month · $0.00 | 3 month · $928.00K 9 month · $1.99M | (m) | (m) |
| 2024-06-30 | $1.00K | $117.04M | $41.00K | $-108.55M | $8.53M | 3 month · $0.00 6 month · $0.00 | 3 month · $598.00K 6 month · $1.06M | (m) | (m) |
| 2024-03-31 | $1.00K | $115.22M | $41.00K | $-106.40M | $8.86M | 3 month · $0.00 | 3 month · $464.00K | (m) | (m) |
| 2023-12-31 | $1.00K | $114.73M | $41.00K | $-104.39M | $10.39M | (m) | 12 month · $1.69M | (m) | (m) |
| 2023-09-30 | (m) | $108.59M | $41.00K | $-102.39M | $6.24M | (m) | 3 month · $383.00K 9 month · $1.37M | (m) | (m) |
| 2023-06-30 | (m) | $108.20M | $41.00K | $-100.01M | $8.23M | (m) | 3 month · $472.00K 6 month · $988.00K | (m) | (m) |
| 2023-03-31 | (m) | $107.73M | $41.00K | $-97.69M | $10.08M | (m) | 3 month · $516.00K | (m) | (m) |
| 2022-12-31 | (m) | $107.21M | $41.00K | $-95.50M | $11.75M | (m) | 12 month · $2.25M | (m) | (m) |
| 2022-09-30 | (m) | $106.73M | $41.00K | $-92.46M | $14.31M | (m) | 3 month · $110.00K 9 month · $1.77M | (m) | (m) |
| 2022-06-30 | (m) | $106.62M | $41.00K | $-89.39M | $17.27M | (m) | 3 month · $696.00K 6 month · $1.66M | (m) | (m) |
| 2022-03-31 | (m) | $105.91M | $41.00K | $-86.21M | $19.75M | (m) | 3 month · $964.00K | (m) | (m) |
| 2021-12-31 | (m) | $104.95M | $41.00K | $-82.43M | $22.57M | 12 month · $0.00 | 12 month · $1.86M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | $26.28M | 9 month · $0.00 | 3 month · $628.00K 9 month · $1.49M | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | $26.28M | 6 month · $0.00 | 3 month · $538.00K 6 month · $865.00K | $41.00K | $-87.54M |
| 2021-03-31 | (m) | (m) | (m) | (m) | $15.65M | 3 month · $0.00 | 3 month · $327.00K | (m) | (m) |
| 2020-12-31 | (m) | $77.71M | $41.00K | $-70.24M | $7.51M | 12 month · $0.00 | 12 month · $901.00K | $41.00K | $-72.89M |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $41.00K | $-69.02M |
| 2019-12-31 | (m) | (m) | (m) | (m) | $13.77M | (m) | (m) | $41.00K | $-62.91M |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $41.00K | $-52.12M |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $41.00K | $-41.81M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |